Ginkgo Bioworks $DNA has been quietly building momentum among biopharma, agriculture, and government (BAG) customers. This core group drove 70% of Q2 2024 revenue, up from 33% at the start of 2021. It could help accelerate the turnaround. DV: www.living.tech/data-visual/...
Biopharma, agriculture, and government customers accounted for 70% of Cell Engineering segment revenue in mid-2024, up from 33% in early 2021.
Amgen $AMGN is conducting a 6,000 patient study to evaluate if olpasiran can reduce the risk of cardiovascular disease. Designed by Arrowhead Pharma $ARWR , the RNAi drug candidate reduces apolipoprotein(a) regardless of cholesterol or LDL levels. Results expected late 2026.
Opinion | The Synthetic Biology Ideology This week's article explores why the storytelling and perception of synthetic biology companies often deviate from the realities of the underlying businesses. #biotech#synbio#livingtechwww.living.tech/articles/opi...
One quarter through the
Guardant Health's Next Big Challenge: Reimbursement The Shield diagnostic candidate is likely to earn FDA approval, but might struggle to earn favorable CMS reimbursement. That could complicate launch -- and Guardant Health's $GH existence. $EXAS www.living.tech/articles/gua...
Shield is likely to become the second blood test approved to screen for colon cancer, but reimbursement coverage might disappoint investors and complicate commercial launch.
7/ Many more insights in the article. This scatter plot near the end is interactive (as are all graphics). It captures every blockbuster in 2023 ranked by Total Sales, U.S. Sales, and Rest of World Sales. Blockbusters with >$5B in revenue from: ➡️ U.S. = 15 ➡️ Ex-U.S. = 3
6/ We also took a deeper dive into the top 3 blockbusters in 2023: Keytruda from Merck $MRK , Humira from AbbVie $ABBV , and Ozempic from Novo Nordisk $NVO . Ozempic was used off-label for obesity, but it notched a record for 6th year sales of any drug product in history.
5/ Blockbuster drugs were equally likely to be a biologic or small molecule in 2023. However, the top 20 (70%), top 50 (56%), and autoimmune therapies (82%) were more likely to be biologics. Oncology (43%) and cardiometabolic (35%) drugs less likely to be biologics.
3/ Only 29 drug developers wielded a blockbuster drug in 2023. It's not an easy milestone for smaller or newly commercial companies to achieve. That count includes Adcetris from SeaGen, which was acquired by Pfizer $PFE later in the year.
2/ Eight (8) blockbusters had sales >$10 billion in 2023. For perspective, 5 years ago only one crossed this level (Humira) – and only 4 had reached this milestone in history as of 2018 (+Lipitor, Sovaldi, and Harvoni). This table is searchable and sortable in the article.
